|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:acquisition
|
gptkb:Merck_&_Co.
|
|
gptkbp:advances
|
new discoveries
|
|
gptkbp:advocacy
|
support initiatives
|
|
gptkbp:biopharmaceutical_innovations
|
leading-edge technologies
|
|
gptkbp:biopharmaceutical_research
|
cutting-edge science
|
|
gptkbp:biopharmaceutical_sector
|
active contributor
|
|
gptkbp:biotech_developments
|
emerging therapies
|
|
gptkbp:biotech_innovations
|
transformative therapies
|
|
gptkbp:biotech_sector
|
active participant
|
|
gptkbp:business_model
|
biopharmaceutical development
|
|
gptkbp:can_lead_to
|
gptkb:Luspatercept
|
|
gptkbp:clinical_research_initiatives
|
focused studies
|
|
gptkbp:clinical_trial
|
gptkb:pharmaceuticals
Phase 3 trials
ongoing studies
measurable outcomes
ongoing evaluations
published findings
published results
evidence-based studies
|
|
gptkbp:collaboration
|
gptkb:Celgene_Corporation
|
|
gptkbp:collaborations
|
academic institutions
joint ventures
academic collaborations
global partners
|
|
gptkbp:community_involvement
|
health initiatives
|
|
gptkbp:conflict
|
competitive landscape
|
|
gptkbp:drug_candidates
|
various stages of development
|
|
gptkbp:drug_development_process
|
rigorous testing
|
|
gptkbp:drug_discovery
|
advanced methodologies
|
|
gptkbp:drug_efficacy
|
demonstrated effectiveness
|
|
gptkbp:economic_development
|
expanding operations
|
|
gptkbp:financial_performance
|
publicly reported
|
|
gptkbp:financials
|
venture capital funding
|
|
gptkbp:focus
|
development of therapies for rare diseases
|
|
gptkbp:founded
|
gptkb:2004
|
|
gptkbp:founder
|
gptkb:John_R._Mc_Gowan
|
|
gptkbp:funding
|
grants and investments
|
|
gptkbp:future_prospects
|
promising developments
|
|
gptkbp:has_advisory_board
|
renowned experts
|
|
gptkbp:headquarters
|
gptkb:Cambridge,_Massachusetts
|
|
gptkbp:healthcare
|
cutting-edge research
innovative approaches
FDA processes
|
|
gptkbp:healthcare_advancements
|
significant progress
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Acceleron Pharma
|
|
gptkbp:initiatives
|
focused studies
|
|
gptkbp:instruction_set
|
multiple candidates
|
|
gptkbp:invention
|
patents filed
|
|
gptkbp:investment
|
active engagement
Venture capital firms
|
|
gptkbp:investment_focus
|
rare blood disorders
|
|
gptkbp:is_effective_against
|
demonstrated results
|
|
gptkbp:leadership
|
M. A. (Marty) Dyer
|
|
gptkbp:market
|
informed strategies
|
|
gptkbp:market_position
|
growing footprint
|
|
gptkbp:marketing_strategy
|
targeted therapies
|
|
gptkbp:notable_products
|
gptkb:Reblozyl
|
|
gptkbp:notable_technology
|
novel therapies
|
|
gptkbp:number_of_employees
|
over 100
|
|
gptkbp:partnership
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:partnerships
|
pharmaceutical companies
collaborative efforts
collaborative research efforts
|
|
gptkbp:patient_population
|
specific demographics
|
|
gptkbp:product
|
innovative solutions
|
|
gptkbp:publications
|
peer-reviewed journals
|
|
gptkbp:regulatory_compliance
|
gptkb:FDA
compliance with guidelines
|
|
gptkbp:research
|
focused on biology
|
|
gptkbp:research_areas
|
hematology
various indications
focused investigations
|
|
gptkbp:research_focus
|
muscle diseases
specific diseases
|
|
gptkbp:side_effect
|
significant contributions
|
|
gptkbp:stock_exchange
|
gptkb:NASDAQ
|
|
gptkbp:stock_symbol
|
XLRN
|
|
gptkbp:team
|
experienced executives
|
|
gptkbp:therapeutic_advancements
|
new treatments
|
|
gptkbp:treatment
|
improved quality of life
improved patient health
|
|
gptkbp:type_of_care
|
community outreach
enhanced services
|
|
gptkbp:website
|
www.acceleronpharma.com
|
|
gptkbp:bfsParent
|
gptkb:Merck_&_Co.
|
|
gptkbp:bfsLayer
|
4
|